Jump to content

Gilgamesh Pharmaceuticals

Add links
From Wikipedia, the free encyclopedia
Gilgamesh Pharmaceuticals
IndustryPharmaceutical; Psychedelic medicine
Founded2019; 6 years ago (2019)[1]
Websitewww.gilgameshpharmaceutical.com

Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines.[2][3][4] It is a "discovery stage" company and is focused on developing new chemical entities.[1]

Its drug candidates include the ketamine-related NMDA receptor antagonist blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine or (R)-4-FDCK), the dimethyltryptamine (DMT)-related serotonergic psychedelic bretisilocin (GM-2505; 5-fluoro-N-methyl-N-ethyltryptamine or 5F-MET), the noribogaine-related κ-opioid receptor agonist GM-3009, and the non-hallucinogenic psychoplastogen GM-5022.[2][3][5][6][4] Another potential candidate is GM-2040, a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist.[7]

The company was co-founded by Jonathan Sporn, Jeff Witkin, Dalibor Sames, Andrew Kruegel, and Mike Cunningham.[1] Cunningham is a research scientist at Gilgamesh.[8] Sames, Kruegel, and Cunningham have worked together at Sames's lab at Columbia University.[1]

In May 2024, AbbVie made an optional deal with Gilgamesh Pharmaceuticals to pay $65 million upright for rights to novel non-hallucinogenic psychoplastogens.[1][9][10] It also agreed to pay up to $1.95 billion for a series of psychoplastogens.[1][9][10]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "Gilgamesh Pharmaceuticals". Psychedelic Science Review. Retrieved 20 February 2025.
  2. ^ a b Gunther, Marc (31 January 2023). "Gilgamesh Tweaks Known Psychedelics To Improve Therapies". Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness. Retrieved 20 February 2025.
  3. ^ a b Taylor, Phil (15 May 2024). "AbbVie takes option on Gilgamesh CNS drugs in $2bn deal". pharmaphorum. Retrieved 20 February 2025. The startup's in-house projects include GM-1020, a small-molecule NMDA receptor channel blocker – the mechanism of action for ketamine – which is in phase 2a clinical development for major depressive disorder (MDD). GM-1020 could provide an oral alternative to Johnson & Johnson's intranasally-administered ketamine-based therapy Spravato (esketamine), which has been approved by the FDA for treatment-resistant depression and MDD with suicidal ideation or behaviour. Also in Gilgamesh's pipeline are GM-2505, a short-acting serotonin 5-HT2A agonist in phase 2 for MDD, an oral neuroplastogen GM-5022 under evaluation for anxiety, depression, and other disorders, as well as GM-3009, an ibogaine analogue designed to have improved safety that Gilgamesh says has potential in PTSD, traumatic brain injury, and substance use disorders.
  4. ^ a b Baum, Stephanie (19 February 2025). "Delving into the Latest Updates on Gilgamesh Pharmaceuticals, Inc. with Synapse". Synapse. Retrieved 20 February 2025.
  5. ^ Barton, Cheryl (18 June 2024). "Neuroplastogens: A novel approach to treat neurological diseases". pharmaphorum. Retrieved 20 February 2025.
  6. ^ Shah, Arsalan (11 July 2024). "Exploring Psychedelics, Consciousness, and Altered States". The Psychedelic Pulse. Retrieved 20 February 2025.
  7. ^ Hughes, Zoe; Klein, Adam; Dvorak, Dino; Austin, Eric; Kiss, Laszlo; Marek, Gerard; Sporn, Jonathan; Kruegel, Andrew (2023). "22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy". Biological Psychiatry. 93 (9): S102 – S103. doi:10.1016/j.biopsych.2023.02.262.
  8. ^ Jarow, Oshan (24 June 2023). "The largest psychedelic conference in history is surprisingly sane". Vox. Retrieved 20 February 2025.
  9. ^ a b Barrie, Robert (14 May 2024). "AbbVie makes a play for psychiatric treatments with $2bn Gilgamesh collaboration". Pharmaceutical Technology. Retrieved 20 February 2025.
  10. ^ a b Psychedelic Alpha (13 May 2024). "Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals". Psychedelic Alpha. Retrieved 20 February 2025.
[edit]


Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wiki.x.io/w/index.php?title=Gilgamesh_Pharmaceuticals&oldid=1276758086"